ABBV vs PCVX
AbbVie vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
70
Buy
| Metric | ABBV | PCVX |
|---|
| AI Score |
69
|
70
|
| Price |
$249.34
|
$58.08
|
| P/E Ratio |
70.28×
|
-7.60×
|
| ROE |
-129.2%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
0.0%
|
| Debt / Equity |
-11.93×
|
0.04×
|
| Dividend Yield |
2.7%
|
0.0%
|
| RSI (14) |
48.9
|
54.9
|
| Beta |
0.28
|
1.21
|
| Expected Upside |
—
|
+6.2%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus PCVX.
PCVX leads by 1 points.
PCVX scores 70/100 (Buy) versus ABBV at 69/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
PCVX Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value